Literature DB >> 22972971

Skeletal complications of bisphosphonate use: what the radiologist should know.

A E Haworth1, J Webb.   

Abstract

Bisphosphonates are widely used for prevention of fractures in patients at risk, mainly in the presence of osteoporosis and bone metastases. A number of adverse effects of prolonged bisphosphonate treatment have emerged. We would like to highlight the skeletal complications from which a radiologist may be the first healthcare professional to recognise the association with bisphosphonate therapy. We illustrate these complications (namely osteonecrosis of the jaw and less well-known atypical femoral shaft fractures), presenting radiological findings in our patients. Recommendations for safer use of bisphosphonates are included in the conclusion of our review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972971      PMCID: PMC3474040          DOI: 10.1259/bjr/99102700

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  41 in total

1.  Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.

Authors:  Sarah Shock Chan; Zehava Sadka Rosenberg; Keith Chan; Craig Capeci
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

2.  A rational approach to management of alendronate-related subtrochanteric fractures.

Authors:  S Das De; T Setiobudi; L Shen; S Das De
Journal:  J Bone Joint Surg Br       Date:  2010-05

3.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

4.  Hypersensitivity reactions to blood components: document issued by the allergy committee of the French medicines and healthcare products regulatory agency.

Authors:  P M Mertes; A Bazin; F Alla; J Bienvenu; C Caldani; B Lamy; D Laroche; M F Leconte des Floris; J-Y Py; D Rebibo; B Willaert; P Demoly
Journal:  J Investig Allergol Clin Immunol       Date:  2011       Impact factor: 4.333

Review 5.  Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.

Authors:  D B Kimmel
Journal:  J Dent Res       Date:  2007-11       Impact factor: 6.116

6.  Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw.

Authors:  Franca Dore; Luca Filippi; Matteo Biasotto; Silvia Chiandussi; Fabio Cavalli; Roberto Di Lenarda
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

7.  Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

Authors:  Felice S O'Ryan; Sam Khoury; Wendy Liao; Myo M Han; Rita L Hui; David Baer; Daniel Martin; Donald Liberty; Joan C Lo
Journal:  J Oral Maxillofac Surg       Date:  2009-07       Impact factor: 1.895

Review 8.  Bone mineralization density distribution in health and disease.

Authors:  P Roschger; E P Paschalis; P Fratzl; K Klaushofer
Journal:  Bone       Date:  2007-11-12       Impact factor: 4.398

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

View more
  8 in total

Review 1.  Therapy-induced bone changes in oncology imaging with 18F-sodium fluoride (NaF) PET-CT.

Authors:  Najeeb Ahmed; Alyaa Sadeq; Fahad Marafi; Gopinath Gnanasegaran; Sharjeel Usmani
Journal:  Ann Nucl Med       Date:  2022-02-26       Impact factor: 2.668

Review 2.  Atypical femur fractures: a review.

Authors:  Wesley H Bronson; I David Kaye; Kenneth A Egol
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

Review 3.  Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis.

Authors:  H Devlin; J Greenwall-Cohen; J Benton; T L Goodwin; A Littlewood; K Horner
Journal:  Br Dent J       Date:  2017-11-17       Impact factor: 1.626

4.  Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings.

Authors:  Kaycee Walton; Tristan R Grogan; Edwin Eshaghzadeh; Danny Hadaya; David A Elashoff; Tara L Aghaloo; Sotirios Tetradis
Journal:  Dentomaxillofac Radiol       Date:  2018-06-28       Impact factor: 2.419

5.  A case of early detection of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Miyu Mori; Tetsuro Koide; Yuriyo Matsui; Toru Matsuda
Journal:  Indian J Pharmacol       Date:  2015 May-Jun       Impact factor: 1.200

Review 6.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

Review 7.  Imaging findings of bisphosphonate-related osteonecrosis of the jaws: a critical review of the quantitative studies.

Authors:  André Ferreira Leite; Fernanda Dos Santos Ogata; Nilce Santos de Melo; Paulo Tadeu de Souza Figueiredo
Journal:  Int J Dent       Date:  2014-06-11

Review 8.  Atypical femoral fractures from bisphosphonate in cancer patients - Review.

Authors:  Matthew Lockwood; Rajesh Banderudrappagari; Larry J Suva; Issam Makhoul
Journal:  J Bone Oncol       Date:  2019-08-22       Impact factor: 4.491

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.